Merck's KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of ...
KEYNOTE-A18, a Phase 3 trial, showed KEYTRUDA (pembrolizumab) plus concurrent chemoradiotherapy (CRT) improved overall survival (OS) in high-risk locally advanced cervical cancer patients, reducing the risk of death by 33% compared to CRT alone. The results were presented at the ESMO Congress 2024 and published in The Lancet.
Related Clinical Trials
Reference News
Pembrolizumab plus chemoradiotherapy improved overall survival in high-risk locally advanced cervical cancer, reducing the risk of death by 33%.
Pembrolizumab combined with chemoradiotherapy significantly improved survival in high-risk locally advanced cervical cancer patients compared to chemoradiotherapy alone, with a 36-month overall survival rate of 82.6% vs 74.8%. The study, ENGOT-cx11/GOG-3047/KEYNOTE-A18, also showed a manageable safety profile and no impact on quality of life.
Pembrolizumab plus chemoradiotherapy significantly improved 36-month overall survival (82.6%) vs chemoradiotherapy alone (74.8%) in high-risk locally advanced cervical cancer patients, according to the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. The hazard ratio for death was under 1 in all subgroups except those aged 65 and older. The study involved 1060 patients with high-risk disease, randomized to receive pembrolizumab or placebo plus chemoradiotherapy followed by the same agent. The treatment showed manageable safety and did not impact quality of life.
Pembrolizumab combined with chemoradiotherapy and continued as monotherapy significantly improves survival in high-risk locally advanced cervical cancer patients, with a 36-month overall survival rate of 82.6% vs 74.8% with chemoradiotherapy alone, according to the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
KEYNOTE-A18, a Phase 3 trial, showed KEYTRUDA (pembrolizumab) plus concurrent chemoradiotherapy (CRT) improved overall survival (OS) in high-risk locally advanced cervical cancer patients, reducing the risk of death by 33% compared to CRT alone. The results were presented at the ESMO Congress 2024 and published in The Lancet.
Pembrolizumab plus chemoradiotherapy significantly improved overall survival in patients with locally advanced cervical cancer, according to the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial. The 36-month survival rate was 82.6% in the pembrolizumab group vs 74.8% in the control group, supporting this immunochemoradiotherapy strategy as a new standard of care.